Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2021

Open Access 01-12-2021 | Hypophosphatemic Rickets | Case report

A bedridden young lady with hypophosphatemic rickets treated with denosumab: a case report

Authors: Butheinah A. Al-Sharafi, Nuha A. Al-Yousfi, Said A. Bamashmus

Published in: Journal of Medical Case Reports | Issue 1/2021

Login to get access

Abstract

Background

Hypophosphatemic rickets is associated with delayed walking, bone deformities, growth failure and physical dysfunction that can limit daily activities. Treatment consists of phosphate salts and calcitriol. We report a case that received denosumab with marked improvement in her condition.

Case presentation

A 24-year-old Yemeni female with hypophosphatemic rickets presented to an endocrinologist with severe weakness and severe pain in the extremities, she had been bedridden for the last 4 years. Bone density showed severe osteoporosis (T score of hip was − 5.0 and Z score of hip was − 5.0, T score of the spine was − 6.0 and Z score of the spine was − 6.1) so the patient was started on denosumab in addition to calcitriol and after 7months she was feeling stronger and felt she could stand assisted and was walking with assistance within 9 months and after 1.5 years of treatment she was walking unassisted.

Conclusion

Denosumab is an effective treatment for osteoporosis, we used it in our patient in addition to calcitriol because she had severe osteoporosis due to long standing hypophosphatemic rickets that had not been treated properly, the patient improved markedly and regained the ability to walk again after being bedridden for 4 years. It may be a drug to consider in such cases although further studies need to be done to confirm this.
Literature
1.
go back to reference Feng JQ, Clinkenbeard EI, Yuan B, et al. Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia. Bone. 2013;54:213–21.CrossRef Feng JQ, Clinkenbeard EI, Yuan B, et al. Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia. Bone. 2013;54:213–21.CrossRef
2.
go back to reference Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3:R13–30.CrossRef Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3:R13–30.CrossRef
3.
go back to reference Emma F, Cappa M, Antoniazzi M, et al. X-linked hypophosphatemic rickets: an Italian experts’ opinion survey. Ital J Pediatr. 2019;45:67.CrossRef Emma F, Cappa M, Antoniazzi M, et al. X-linked hypophosphatemic rickets: an Italian experts’ opinion survey. Ital J Pediatr. 2019;45:67.CrossRef
4.
go back to reference Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378:1987–98.CrossRef Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378:1987–98.CrossRef
5.
go back to reference Upfill-Brown A, Bukata S, Bernthal NM, et al. Use of denosumab in children with osteoclast bone dysplasias: report of three cases. JBMR Plus. 2019;3(10):e10210.CrossRef Upfill-Brown A, Bukata S, Bernthal NM, et al. Use of denosumab in children with osteoclast bone dysplasias: report of three cases. JBMR Plus. 2019;3(10):e10210.CrossRef
6.
go back to reference Kunii T, Lijima T, Jojima T, et al. Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report. J Med Case Reports. 2019;13:99.CrossRef Kunii T, Lijima T, Jojima T, et al. Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report. J Med Case Reports. 2019;13:99.CrossRef
7.
go back to reference Hoyer-Kuhn H, Rehberg M, Netzer C, et al. Individualized treatment with denosumab in children with osteogensis imerfecta- follow up of a trial cohort. Orphanet J Rare Dis. 2019;14:219.CrossRef Hoyer-Kuhn H, Rehberg M, Netzer C, et al. Individualized treatment with denosumab in children with osteogensis imerfecta- follow up of a trial cohort. Orphanet J Rare Dis. 2019;14:219.CrossRef
8.
go back to reference Semier O, Rehberg M, Mehdiani N, et al. Current and emerging therapeutic options for the management of rare skeletal diseases. Paediatr Drugs. 2019;21(2):95–106.CrossRef Semier O, Rehberg M, Mehdiani N, et al. Current and emerging therapeutic options for the management of rare skeletal diseases. Paediatr Drugs. 2019;21(2):95–106.CrossRef
9.
go back to reference Rivkees SA, El-Hajj-Fuleihan G, Brown EM, et al. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab. 1992;75:1514–8.PubMed Rivkees SA, El-Hajj-Fuleihan G, Brown EM, et al. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab. 1992;75:1514–8.PubMed
10.
go back to reference Sullivan W, Carpenter T, Glorieux F, et al. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 1992;75:879–85.PubMed Sullivan W, Carpenter T, Glorieux F, et al. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 1992;75:879–85.PubMed
11.
go back to reference Brownstein CA, Adler F, Nelson-Williams C, et al. A translocation causing increased α-Klotho level results in hypophosphatemic rickets and hyperparathyroidism. PNAS. 2008;105:3455–60.CrossRef Brownstein CA, Adler F, Nelson-Williams C, et al. A translocation causing increased α-Klotho level results in hypophosphatemic rickets and hyperparathyroidism. PNAS. 2008;105:3455–60.CrossRef
Metadata
Title
A bedridden young lady with hypophosphatemic rickets treated with denosumab: a case report
Authors
Butheinah A. Al-Sharafi
Nuha A. Al-Yousfi
Said A. Bamashmus
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2021
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-020-02654-9

Other articles of this Issue 1/2021

Journal of Medical Case Reports 1/2021 Go to the issue